Agios Submits Supplemental New Drug Application to FDA for TIBSOVO® (ivosidenib tablets) for Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

Matthew Durham
Omnidynamic Marketing

Pat Purcell
Meeting Engagement

Bud Bilanich
Success Coach

Amy Giles
Increasing Engagement

David Linetsky
Point-of-Care Marketing

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

Frank Burrell
Scientific Storytelling

Brenda Snow
Authentic Patient Voice

Paul Theisen
Patient Acquisition

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment